https://de.marketscreener.com/kurs/aktie/4SC-AG-22033427/news/4SC-AG-Positive-Sicherheitsdaten-aus-Phase-Ib-II-Studie-EMERGE-mit-Domatinostat-Avelumab-im-Magen-28955328/?utm_source=telegram&utm_medium=social&utm_campaign=share